The Korea Food and Drug Administration has posted a warning against thalidomide, which is used to treat multiple myeloma.
The announcement followed a similar measure posted by German authorities, which reported possible side-effects including myocardiac infarction, cerebrovascular disease and others.
The KFDA plans to conduct further studies that will be reflected in the future authorization of the material. Currently, thalidomide is sold in three items by two pharmaceutical firms including Celgene Thalidomide Capsule 50 mg. The manufacturers have verified some side-effects of its products already.